Compare BVFL & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVFL | PROK |
|---|---|---|
| Founded | 1873 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.2M | 417.1M |
| IPO Year | N/A | N/A |
| Metric | BVFL | PROK |
|---|---|---|
| Price | $18.53 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 20.4K | ★ 1.3M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $38,669,000.00 | $744,000.00 |
| Revenue This Year | N/A | $956.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.23 | ★ N/A |
| Revenue Growth | ★ 1.69 | N/A |
| 52 Week Low | $13.53 | $0.46 |
| 52 Week High | $19.74 | $7.13 |
| Indicator | BVFL | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 43.72 |
| Support Level | $18.02 | $2.33 |
| Resistance Level | $18.68 | $2.59 |
| Average True Range (ATR) | 0.43 | 0.16 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 12.10 | 26.42 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.